Document is current
Any future updates will be listed below
-
Authors
Leo, Isabelle Rose http://orcid.org/0000-0002-7627-6690
Aswad, Luay http://orcid.org/0000-0002-8730-9208
Stahl, Matthias http://orcid.org/0000-0002-0176-9386
Kunold, Elena
Post, Frederik http://orcid.org/0000-0003-0376-1326
Erkers, Tom
Struyf, Nona http://orcid.org/0000-0002-6975-0753
Mermelekas, Georgios
Joshi, Rubin Narayan
Gracia-Villacampa, Eva http://orcid.org/0000-0003-0353-2101
Östling, Päivi
Kallioniemi, Olli P.
Tamm, Katja Pokrovskaja http://orcid.org/0000-0001-6359-1256
Siavelis, Ioannis
Lehtiö, Janne http://orcid.org/0000-0002-8100-9562
Vesterlund, Mattias http://orcid.org/0000-0001-9471-6592
Jafari, Rozbeh http://orcid.org/0000-0002-3396-4709
-
Funding
Funding for this research was provided by:
Barncancerfonden (TJ2016-0035, PR2016-0019 and PR2019-0025, TJ2019-0023 and PR2019-0071)
Vetenskapsrådet (2017-01653, 2019-04830)
Stiftelsen Felix Mindus Bidrag till Leukemiforskningen (R.J.)
Cancerföreningen i Stockholm (174182, 194111 and 181173)
Dr Åke Olssons Stiftelse för Haematologisk Forskning (2017-00437 and 2021-00130)
Magnus Bergvalls Stiftelse (2017-02421 and 2016-01841)
- License Information
-
More Information
Article History
Received: 20 April 2021
Accepted: 2 March 2022
First Online: 30 March 2022
Competing interests
: J.L. reports receiving honoraria for speaker activities from Pfizer and Roche, institutional research support as a PI from AstraZeneca, Novartis, GE Healthcare (unrelated to this study), and is cofounder and shareholder of FenoMark Diagnostics Ab (unrelated to this study). J.L. and I.S. are coinventors on a patent application (unrelated to this study). The remaining authors declare no competing interests.
